On Oct 1, 2025, the United States plans to impose a 100% tariff on imports of branded or patented pharmaceutical products, with exemptions for companies that have already broken ground on new US manufacturing.
On Oct 1, 2025, the United States plans to impose a 100% tariff on imports of branded or patented pharmaceutical products, with exemptions for companies that have already broken ground on new US manufacturing.
We evaluated each NIFTY Pharma constituent on four dimensions: (1) US revenue exposure (qualitative), (2) US manufacturing presence, (3) branded/specialty exposure in the US, and
Weighted Index Risk (WIR): 1.49 on a 1–5 scale.
Index weights: NIFTY Pharma factsheet as of Aug 29, 2025 (top 10); residual 10 names apportioned equally across remaining weight.
On Oct 1, 2025, the United States plans to impose a 100% tariff on imports of branded or patented pharmaceutical products, with exemptions for companies that have already broken ground on new US manufacturing. Generics are not targeted. For NIFTY Pharma (India), direct tariff risk is concentrated in specialty/branded products sold into the US and in firms without flexible US manufacturing options. API-focused firms face minimal direct risk; indirect effects (sourcing, partner behavior) remain watch items.
We evaluated each NIFTY Pharma constituent on four dimensions: (1) US revenue exposure (qualitative), (2) US manufacturing presence, (3) branded/specialty exposure in the US, and
Weighted Index Risk (WIR): 1.49 on a 1–5 scale. Risk is skewed toward US-heavy generic players with some specialty brands (e.g., Sun) and toward companies without deep US manufacturing buffers (if any). API-centric players like Divi’s score lowest.
| Company | Inde x Weig ht % | US Expos ure | US Exposure Notes | US Manufacturing | US Branded/Speci alty | Tari ff Ris k (1– 5) |
|---|---|---|---|---|---|---|
| Sun Pharmaceut ical Industries Ltd | 21.99 | High | Americas/US a major market; specialty brands like Ilumya/Cequ a sold in US | Yes — Ohm Laboratories, New Brunswick/Cra nbury, NJ | High (specialty brands incl. Ilumya, Cequa) | 2.0 |
| Cipla Ltd | 11.43 | Mediu | FY25 North | Yes — InvaGen | Low-Medium | 1.5 |
| m | America revenue about $0.93bn; meaningful but diversified | Pharmaceutical s sites in NY/MA | (largely generics; respiratory devices) | |||
|---|---|---|---|---|---|---|
| Divi's Laboratorie s Ltd | 9.96 | Low | Primarily API exporter; limited finished-drug imports into US | No — Global API plants in India; not US FDF | N/A (APIs) | 1.0 |
| Dr. Reddy's Laboratorie s Ltd | 9.81 | High | US is a key market; multiple US manufacturin g sites | Yes — Shreveport, LA; Bristol, TN; Middleburgh, NY | Low (generics/OTC dominant) | 1.5 |
| Lupin Ltd | 5.86 | High | North America ~38% of revenue; sizeable US generic portfolio | Yes — Somerset, New Jersey manufacturing site | Low (largely generics) | 1.5 |
| Torrent Pharmaceut icals Ltd | 4.76 | Low | US ~10% of revenue; India-heavy mix; some USFDA- approved sites | Yes — Levittown, Pennsylvania facility (USFDA- inspected) | Low (largely generics/India brands) | 1.0 |
| Laurus Labs Ltd | 4.29 | Low | Predominant ly APIs/CDMO; limited US finished-dose exposure | No — API/CDMO sites concentrated in India | N/A (APIs/CDMO) | 1.0 |
| Glenmark Pharmaceut icals Ltd | 3.70 | Mediu m | US generics meaningful; owns Monroe, NC plant | Yes — Monroe, North Carolina plant | Low (generics) | 1.0 |
| Aurobindo Pharma Ltd | 3.68 | High | US is largest market; extensive US portfolio, R&D and manufacturin | Yes — Aurolife (Dayton, NJ) + Durham, NC R&D; new East Windsor, NJ facility | Low (generics; some specialty/inject ables) | 1.5 |
| g footprint | ||||||
|---|---|---|---|---|---|---|
| Alkem Laboratorie s Ltd | 3.65 | Mediu m | US is meaningful but not dominant; mostly generics | No — US presence via ANDAs; no known US FDF plant | Low (generics) | 1.5 |
| Ipca Laboratorie s Ltd | 2.09 | Low- Mediu m | Re-entry into US; exposure rising but modest | No — Primarily India-based manufacturing; re-entering US | Low (re-entry, generics) | 1.5 |
| Mankind Pharma Ltd | 2.09 | Low | Primarily India branded generics/OT C | No — India- focused manufacturing | Low (India brands/OTC) | 1.0 |
| Ajanta Pharma Ltd | 2.09 | Low- Mediu m | US generics present but modest vs India/EM | No — Manufacturing in India; US distribution | Low (generics) | 1.5 |
| JB Chemicals & Pharmaceut icals Ltd | 2.09 | Low | India/emergi ng markets- focused; limited US sales | No — India- centric manufacturing base | Low (India brands) | 1.0 |
| Zydus Lifesciences Ltd | 2.09 | High | US formulations ~49% of revenue in recent quarter | Yes — Nesher Pharmaceutical s, St. Louis region, MO | Low (generics; some brands) | 1.5 |
| Granules India Ltd | 2.09 | Mediu m | Meaningful US formulations & APIs; still largely generic | No — Manufacturing in India; US distribution | Low (generics/APIs) | 1.5 |
| Abbott India Ltd | 2.09 | Low | India-focused branded generics; minimal US exposure | No — India- focused subsidiary of Abbott | Low (India branded generics; not US) | 1.0 |
| Gland Pharma Ltd | 2.09 | High | US is a key market for injectables/C DMO | No — Injectables plants in India; US distribution | Low (injectable generics/CDMO ) | 2.0 |
| Biocon Ltd | 2.09 | Mediu m-High | Large US biosimilars | Yes — Cranbury, NJ | Medium (biosimilars; | 2.0 |
| footprint via Biocon Biologics; also OSD facility in NJ | OSD facility; biosimilar manufacturing largely ex-US | classification ambiguity vs 'branded') | ||||
|---|---|---|---|---|---|---|
| Alembic Pharmaceut icals Ltd | 2.09 | Mediu m | US generics meaningful; no known US FDF manufacturin g | No — India- based sites; sizeable US ANDA portfolio | Low (generics) | 1.5 |
Index weights: NIFTY Pharma factsheet as of Aug 29, 2025 (top 10); residual 10 names apportioned equally across remaining weight. Qualitative exposure and manufacturing presence compiled from public disclosures and company sites as of report date.
Tariffs are administered at the Harmonized Tariff Schedule (HTS) line level, while 'branded/patented' is not a customs classification. For operationalization, agencies must map the policy to HS 30xx lines and then define a rule that ties branded/patented status to NDA/BLA (Orange/Purple Book) at entry. Expect initial ambiguity, self‑certification, and audits. Tactical read: enforcement may be uneven early on, presenting a timing window for re‑routing and documentation design.
Even if a firm moves finishing/packaging to the US, most changes trigger manufacturing supplements. Prior‑Approval Supplements (PAS) can have 4–6 month goal dates (and 8–10 months if inspections are required). Plan for dual‑sourcing, bridging inventory, and staggered filings to avoid supply cliffs.
If the exemption hinges on a project with 'construction started', acquiring a target with an already‑in‑progress US site (or restarting a paused build) could qualify sooner than greenfield. Expect competitive bidding for half‑built facilities and quick bolt‑ons (brownfield) rather than pure greenfield.
Because the tariff targets finished branded imports, one practical workaround is to import APIs/intermediates and perform US fill‑finish/release via CMOs. This shifts value‑add stateside while preserving India’s API lead. Downside: sterile capacity is tight; QA/tech‑transfer bottlenecks are real.
If landed costs spike for branded imports, PBMs have incentive to push harder on step‑edits and substitution. This can raise generic penetration, benefiting Indian Gx—provided there is capacity and FDA compliance headroom.
In the event of a medically necessary shortage, US agencies can grant targeted relief. Firms maintaining transparent shortage dashboards and proactive FDA communication may secure exemptions faster.
Biosimilars are licensed under BLAs and often marketed with brand names but typically lack active patent shields. If the rule keys off 'patented', biosimilars could be spared; if it keys off 'branded', exposure rises. Maintain two playbooks pending legal text.
Recent revocation of low‑value shipment exemptions means more FDA scrutiny of all inbound lots. Expect longer clearance times and tighter document hygiene at ports; factor that into cycle stock.
Puerto Rico retains deep pharma infrastructure and incentives. Expect renewed interest for quick US‑soil manufacturing, especially for oral solids and some sterile lines with refurbishment potential.
Even with US finishing, API and key intermediate demand can grow. API leaders (e.g., Divi’s, Laurus) can win on upstream volumes and higher value CDMO/HPAPI work while innovators localize the last mile in the US.
This report is for informational purposes only and does not constitute investment advice. While efforts have been made to ensure accuracy, no warranty is expressed or implied. Investors should perform their own due diligence and consider consulting a qualified advisor.
This research is for information and education only and is not investment advice. Figures may be provisional. Oorjita.AI and its authors may hold positions in securities mentioned. Please consult a SEBI-registered investment adviser before making investment decisions. Published Friday, 26 September 2025, 2:44 PM IST.
All four layers aligned bearish. A/D = capitulation breadth.
India's Monday session closed positively as Nifty 50 settled at 25,713.00 (+141.75 points, +0.55%) and Sensex rallied approximately 350+ points, led by PSU banks and financial stocks.
Amagi Media Labs IPO closes for subscription, FII/DII flow trends continue, and technical levels around 25,700 for Nifty remain critical as markets resume after the mid-week break.
